These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 20709547)

  • 1. The discovery and synthesis of highly potent subtype selective phosphodiesterase 4D inhibitors.
    Aspiotis R; Deschênes D; Dubé D; Girard Y; Huang Z; Laliberté F; Liu S; Papp R; Nicholson DW; Young RN
    Bioorg Med Chem Lett; 2010 Sep; 20(18):5502-5. PubMed ID: 20709547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors.
    Lacombe P; Chauret N; Claveau D; Day S; Deschênes D; Dubé D; Gallant M; Girard Y; Huang Z; Laliberté F; Lévesque JF; Liu S; Macdonald D; Mancini JA; Masson P; Nicholson DW; Nicoll-Griffith DA; Salem M; Styhler A; Young RN
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5266-9. PubMed ID: 19640717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled administration.
    Woodrow MD; Ballantine SP; Barker MD; Clarke BJ; Dawson J; Dean TW; Delves CJ; Evans B; Gough SL; Guntrip SB; Holman S; Holmes DS; Kranz M; Lindvaal MK; Lucas FS; Neu M; Ranshaw LE; Solanke YE; Somers DO; Ward P; Wiseman JO
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5261-5. PubMed ID: 19656678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.
    Macdonald D; Mastracchio A; Perrier H; Dubé D; Gallant M; Lacombe P; Deschênes D; Roy B; Scheigetz J; Bateman K; Li C; Trimble LA; Day S; Chauret N; Nicoll-Griffith DA; Silva JM; Huang Z; Laliberté F; Liu S; Ethier D; Pon D; Muise E; Boulet L; Chan CC; Styhler A; Charleson S; Mancini J; Masson P; Claveau D; Nicholson D; Turner M; Young RN; Girard Y
    Bioorg Med Chem Lett; 2005 Dec; 15(23):5241-6. PubMed ID: 16168647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors.
    Gallant M; Chauret N; Claveau D; Day S; Deschênes D; Dubé D; Huang Z; Lacombe P; Laliberté F; Lévesque JF; Liu S; Macdonald D; Mancini J; Masson P; Mastracchio A; Nicholson D; Nicoll-Griffith DA; Perrier H; Salem M; Styhler A; Young RN; Girard Y
    Bioorg Med Chem Lett; 2008 Feb; 18(4):1407-12. PubMed ID: 18207397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quinolines as a novel structural class of potent and selective PDE4 inhibitors: optimisation for oral administration.
    Lunniss CJ; Cooper AW; Eldred CD; Kranz M; Lindvall M; Lucas FS; Neu M; Preston AG; Ranshaw LE; Redgrave AJ; Ed Robinson J; Shipley TJ; Solanke YE; Somers DO; Wiseman JO
    Bioorg Med Chem Lett; 2009 Mar; 19(5):1380-5. PubMed ID: 19195882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of pyridazino[4,5-b]indolizines as selective PDE4B inhibitors.
    Donnell AF; Dollings PJ; Butera JA; Dietrich AJ; Lipinski KK; Ghavami A; Hirst WD
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2163-7. PubMed ID: 20202838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Catecholic amides as potential selective phosphodiesterase 4D inhibitors: Design, synthesis, pharmacological evaluation and structure-activity relationships.
    Zhou ZZ; Ge BC; Chen YF; Shi XD; Yang XM; Xu JP
    Bioorg Med Chem; 2015 Nov; 23(22):7332-9. PubMed ID: 26526739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nitrogen-bridged substituted 8-arylquinolines as potent PDE IV inhibitors.
    Lacombe P; Deschênes D; Dubé D; Dubé L; Gallant M; Macdonald D; Mastracchio A; Perrier H; Charleson S; Huang Z; Laliberté F; Liu S; Mancini JA; Masson P; Salem M; Styhler A; Girard Y
    Bioorg Med Chem Lett; 2006 May; 16(10):2608-12. PubMed ID: 16516471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and biological evaluation of 6-(benzyloxy)-4-methylquinolin-2(1H)-one derivatives as PDE3 inhibitors.
    Nikpour M; Sadeghian H; Saberi MR; Nick RS; Seyedi SM; Hosseini A; Parsaee H; Bozorg AT
    Bioorg Med Chem; 2010 Jan; 18(2):855-62. PubMed ID: 20005117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: design, synthesis and structure-activity relationship studies.
    Vergne F; Bernardelli P; Lorthiois E; Pham N; Proust E; Oliveira C; Mafroud AK; Royer F; Wrigglesworth R; Schellhaas J; Barvian M; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Berna P; Soulard P
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4607-13. PubMed ID: 15324874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyrazolopyridines as potent PDE4B inhibitors: 5-heterocycle SAR.
    Mitchell CJ; Ballantine SP; Coe DM; Cook CM; Delves CJ; Dowle MD; Edlin CD; Hamblin JN; Holman S; Johnson MR; Jones PS; Keeling SE; Kranz M; Lindvall M; Lucas FS; Neu M; Solanke YE; Somers DO; Trivedi NA; Wiseman JO
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5803-6. PubMed ID: 20732811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification, synthesis and SAR of amino substituted pyrido[3,2b]pyrazinones as potent and selective PDE5 inhibitors.
    Owen DR; Walker JK; Jon Jacobsen E; Freskos JN; Hughes RO; Brown DL; Bell AS; Brown DG; Phillips C; Mischke BV; Molyneaux JM; Fobian YM; Heasley SE; Moon JB; Stallings WC; Joseph Rogier D; Fox DN; Palmer MJ; Ringer T; Rodriquez-Lens M; Cubbage JW; Blevis-Bal RM; Benson AG; Acker BA; Maddux TM; Tollefson MB; Bond BR; Macinnes A; Yu Y
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4088-91. PubMed ID: 19540112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione analogues.
    Daugan A; Grondin P; Ruault C; Le Monnier de Gouville AC; Coste H; Linget JM; Kirilovsky J; Hyafil F; Labaudinière R
    J Med Chem; 2003 Oct; 46(21):4533-42. PubMed ID: 14521415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a highly potent series of oxazole-based phosphodiesterase 4 inhibitors.
    Kuang R; Shue HJ; Blythin DJ; Shih NY; Gu D; Chen X; Schwerdt J; Lin L; Ting PC; Zhu X; Aslanian R; Piwinski JJ; Xiao L; Prelusky D; Wu P; Zhang J; Zhang X; Celly CS; Minnicozzi M; Billah M; Wang P
    Bioorg Med Chem Lett; 2007 Sep; 17(18):5150-4. PubMed ID: 17683932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of a new series of [1,2,4]triazolo[4,3-a]quinoxalines as dual phosphodiesterase 2/phosphodiesterase 10 (PDE2/PDE10) inhibitors.
    Andrés JI; Buijnsters P; De Angelis M; Langlois X; Rombouts F; Trabanco AA; Vanhoof G
    Bioorg Med Chem Lett; 2013 Feb; 23(3):785-90. PubMed ID: 23260348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 8-Methoxyquinolines as PDE4 inhibitors.
    Billah M; Buckley GM; Cooper N; Dyke HJ; Egan R; Ganguly A; Gowers L; Haughan AF; Kendall HJ; Lowe C; Minnicozzi M; Montana JG; Oxford J; Peake JC; Picken CL; Piwinski JJ; Naylor R; Sabin V; Shih NY; Warneck JB
    Bioorg Med Chem Lett; 2002 Jun; 12(12):1617-9. PubMed ID: 12039575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of selective PDE4B inhibitors.
    Naganuma K; Omura A; Maekawara N; Saitoh M; Ohkawa N; Kubota T; Nagumo H; Kodama T; Takemura M; Ohtsuka Y; Nakamura J; Tsujita R; Kawasaki K; Yokoi H; Kawanishi M
    Bioorg Med Chem Lett; 2009 Jun; 19(12):3174-6. PubMed ID: 19447034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-activity relationships of N-acyl pyrroloquinolone PDE-5 inhibitors.
    Lanter JC; Sui Z; Macielag MJ; Fiordeliso JJ; Jiang W; Qiu Y; Bhattacharjee S; Kraft P; John TM; Haynes-Johnson D; Craig E; Clancy J
    J Med Chem; 2004 Jan; 47(3):656-62. PubMed ID: 14736245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of oxazole-based PDE4 inhibitors with picomolar potency.
    Kuang R; Shue HJ; Xiao L; Blythin DJ; Shih NY; Chen X; Gu D; Schwerdt J; Lin L; Ting PC; Cao J; Aslanian R; Piwinski JJ; Prelusky D; Wu P; Zhang J; Zhang X; Celly CS; Billah M; Wang P
    Bioorg Med Chem Lett; 2012 Apr; 22(7):2594-7. PubMed ID: 22401864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.